|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Late biliary complications in human alveolar echinococcosis are associated with high mortality显示文摘AIM:To evaluate the incidence of late biliary complications in non-resectable alveolar echinococcosis(AE)under long-term chemotherapy with benzimidazoles.METHODS:Retrospective analysis of AE patients with biliary complications occurring more than three years after the diagnosis of AE.We compared characteristics of patients with and without biliary complications,analyzed potential risk factor for biliary complications and performed survival analyses.RESULTS:Ninety four of 148 patients with AE in Zurich had non-resectable AE requiring long-term benzimidazole chemotherapy,of which 26(28%)patients developed late biliary complications.These patients had a median age of 55.5(35.5-65)years at diagnosis of AE and developed biliary complications after 15(8.25-19)years of chemotherapy.The most common biliary complications during long-term chemotherapy were late-onset cholangitis(n=14),sclerosing cholangitis-like lesions(n=8),hepatolithiasis(n=5),affection of the common bile duct(n=7)and secondary biliary cirrhosis(n=7).Thirteen of the 26 patients had undergone surgery(including 12 resections)before chemotherapy.Previous surgery was a risk factor for late biliary complications in linear regression analysis(P=0.012).CONCLUSION:Late biliary complications can be observed in nearly one third of patients with non-resectable AE,with previous surgery being a potential risk factor.After the occurrence of late biliary complications,the median survival is only 3 years,suggesting that late biliary complications indicate a poor prognostic outcome. | Pascal Frei Benjamin Misselwitz Meher K Prakash Alain M Schoepfer Bettina M Prinz Vavricka Beat Müllhaupt Michael Fried Kuno Lehmann Rudolf W Ammann Stephan R Vavricka | 2014 | World Journal of Gastroenterology2014，20，19： | 5 |
| 2 | Mucosal healing and deep remission: What does it mean?显示文摘The use of specific terms under different meanings and varying definitions has always been a source of confusion in science.When we point our efforts towards an evidence based medicine for inflammatory bowel diseases(IBD)the same is true:Terms such as'mucosal healing'or'deep remission'as endpoints in clinical trials or treatment goals in daily patient care may contribute to misconceptions if meanings change over time or definitions are altered.It appears to be useful to first have a look at the development of terms and their definitions,to assess their intrinsic and context-independent problems and then to analyze the different relevance in present-day clinical studies and trials.The purpose of such an attempt would be to gain clearer insights into the true impact of the clinical findings behind the terms.It may also lead to a better defined use of those terms for future studies.The terms'mucosal healing'and'deep remission'have been introduced in recent years as new therapeutic targets in the treatment of IBD patients.Several clinical trials,cohort studies or inception cohorts provided data that the long term disease course is better,when mucosal healing is achieved.However,it is still unclear whether continued or increased therapeutic measures will aid or improve mucosal healing for patients in clinical remission.Clinical trials are under way to answer this question.Attention should be paid to clearly address what levels of IBD activity are looked at.In the present review article authors aim to summarize the current evidence available on mucosal healing and deep remission and try to highlight their value and position in the everyday decision making for gastroenterologists. | Gerhard Rogler Stephan Vavricka Alain Schoepfer Peter L Lakatos | 2013 | World Journal of Gastroenterology2013，19，43： | 4 |
| 3 | Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months显示文摘 | P. Meyrat E. Safroneeva A. M. Schoepfer | 2012 | Aliment Pharmacol Ther (pt)2012，，11： | 3 |
| 4 | Corticosteroid-dependent eosinophilic oesophagitis: azathioprine and 6-mercaptopurine can induce and maintain long-term remission显示文摘 | Peter Netzer Juergen M. Gschossmann Alex Straumann Alexander Sendensky Rosemarie Weimann Alain M. Schoepfer | 2007 | European Journal of Gastroenterology & Hepatology2007，，： | 2 |
| 5 | Budesonide Is Effective in Adolescent and Adult Patients With Active Eosinophilic Esophagitis显示文摘 | Alex Straumann Sebastien Conus Lukas Degen Stephanie Felder Mirjam Kummer Hansjürg Engel Christian Bussmann Christoph Beglinger Alain Schoepfer Hans–Uwe Simon | 2010 | Gastroenterology2010，，： | 2 |
| 6 | Long-Term Budesonide Maintenance Treatment Is Partially Effective for Patients With Eosinophilic Esophagitis显示文摘 | Alex Straumann Sebastien Conus Lukas Degen Cornelia Frei Christian Bussmann Christoph Beglinger Alain Schoepfer Hans–Uwe Simon | 2011 | Clinical Gastroenterology and Hepatology2011，，： | 2 |
| 7 | Diagnosis and Management of the Symptomatic Duodenal Diverticulum: a Case Series and a Short Review of the Literature显示文摘 | Beat Schnueriger Stephan A. Vorburger Vanessa M. Banz Alain M. Schoepfer Daniel Candinas | 2008 | Journal of Gastrointestinal Surgery2008，，9： | 2 |
| 8 | Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months显示文摘 | Meyrat P Safroneeva E Schoepfer AM | 2012 | Aliment Pharmacol Ther2012，36，1112： | 1 |
| 9 | Accuracy of four fecal assays in the diagnosis of colitis显示文摘 | Schoepfer AM Trummler M Seeholzer P | | 0，，10： | 1 |
| 10 | Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI显示文摘 | Schoepfer AM Beglinger C Straumann A | 2010 | Am J Gastroenterol2010，105，1： | 1 |
| 11 | Esophagear dilation in eosinophilic esophagitis: effectiveness, safety, and impact on the underlying inflammation显示文摘 | Schoepfer A M Gonsalves N Bussmann C | 2010 | Am J Gastroenterol2010，105，5： | 1 |
| 12 | Management of blunt injuries to the spleen 显示文摘 | Renzulli P Gross T Schoepfer AM | 2010 | Br J Surg2010，97，16： | 1 |
| 13 | Single-channel analysis of an NMDA receptor possessing a mutation in the region of the glutamate binding site显示文摘 | Anson LC Schoepfer R Colquhoun D | 2000 | J Physiol2000，527，： | 1 |
| 14 | Heteromeric NMDA re- ceptors:molecular and functional distinction of subtypes显示文摘 | Monyer H Sprengel R Schoepfer R | 1992 | Sci- ence1992，256，： | 1 |
| 15 | Heteromeric NMDA receptors: molecular and functional distinction of subtypes显示文摘 | Monyer H Sprengel R Schoepfer R | 1992 | Science1992，256，5060： | 1 |
| 16 | Discriminating IBD from IBS : comparison of the test performance of fecal mark- ers, blood leukocytes, CRP and IBD antibodies 显示文摘 | Schoepfer AM Trummler M Seeholzer P | 2008 | Inflamm Bowel Dis2008，14，1： | 1 |
| 17 | A muscle acetylcholine receptor is expressed in the human cerebellar medulloblastoma cell line TE671显示文摘 | Luther MA Schoepfer R Whiting P etal | 1989 | J Neurosci1989，9，3： | 1 |
| 18 | Fecal cal- protectin correlates more closely with the Simple Endo- scopic Score for Crohnrs disease (SES-CD) than CRP, blood leukocytes,and the CDAI显示文摘 | Schoepfer AM Beglinger C Straumann A | 2010 | Am J Gastroenterol2010，105，1： | 1 |
| 19 | Qrowth-associated proteinGAP-43 and L; act synergistically to promote regenerative growth of Purkinje cell axonsin vivo显示文摘 | Zhang Y Bo X Schoepfer R | 2005 | ProcNailAcad Sci USA2005，102，4： | 1 |
| 20 | Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers显示文摘 | SCHOEPFER AM VAVRICKA S ZAHND-STRAUMANN N | 2012 | J Crohns Colitis2012，6，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员